Replies to post #9462 on Algernon Pharmaceuticals Inc (AGNPF)

[DannyDanboy]

Someone over at the other board mentioned that Algernon may have had to sign an NDA (non disclosure agreement) with the SK regulatory body preliminary to enrollment.

Hence that would indicate once trials commence they cannot speak on it or share any type of data or update the public until trials are fully completed. This would seem feasible and indicative of the way South Korea does things. Quiet and close to the chest.

Just my opinion. GLTA

[GVX808]

I'm not sure if you've traded biotech stocks before, however, over the years I traded more than my share. The "lack of news" is completely normal. I would not expect to hear anything from South Korea until a final report is filed at the end of the trial period.

The news will be sudden and it will hit the share price hard in one direction or the other.

[Money $hot]

What premise are you drawing from that suggests news should be coming from SK by now?

Maybe it's time to re-read about the SK trial in black and white?

The 40-patient, 4-week trial, is designed to test the effect of Ifenprodil in COVID-19 infected patients with severe pneumonia. Patients are randomized in a 1:1 fashion to receive either standard of care (SOC) or SOC with Ifenprodil. The primary endpoint will be the rate at which their lung function improves by measuring oxygen levels in the blood (Pa02/Fi02). Secondary endpoints will include mortality, rate of mechanical ventilation, and patient reported effects on cough and breathlessness (dyspnea).

Enrollment in the phase 2 clinical trial is expected to begin on May 8, 2020.

“This first human trial of Ifenprodil in COVID-19 patients is a major step forward with our new acute lung injury clinical research program,” said Christopher J. Moreau CEO of Algernon. “Positive Phase 2 data would be an important milestone as we continue to investigate Ifenprodil’s therapeutic potential as a treatment for COVID-19, in addition to advancing our idiopathic pulmonary fibrosis and chronic cough program.”

So the SK trial started 12 days ago. That's less than two weeks of a 4 week trial. Furthermore, no one knows how many people have thus far been enrolled. No one knows if anyone has been dosed - "First Patient Dosing". No one knows IF/When the SK trial will end. So now everybody waits since the speeding train to a PP has finally come to a complete halt. Which gives you time to get your facts straight.

Also, as far as the "multinational" clinical trial (Canada/USA/ Australia) for COVID19, I wouldn't expect anything to start prior to Fall 2020. As we can see, management waited for Canadian approval before submitting to Australia. I assume they will wait for approval from Australia before submitting to USA. So full approval by all countries could be months away. Potentially, just in time for the next COVID19 wave to sweep across the USA.

Review 2:35 to 3:25 min/sec mark of latest proactive video.

Moreau explains the strategy behind the "multinational" clinical trial regarding potential difficulties of patient enrollment. I would not be surprised IF their having trouble enrolling patients in SK. I also would not be surprised if that's another reason for the sell off.

SK is said to be the global standard for COVID containment per the World Health Organization.

Algernon couldn't have picked a worse country for a COVID trial at this point in time.

I still don't get why they didn't go at Japan as well for the initial COVID study.

Just 1 opinion,

/////AMG